Triple Negative Breast Cancer, "I Won't Back Down!": Bio-Path's Plan to Develop Liposomal Grb-2 as a Targeted Therapy Against Inflammatory Breast Cancer and Triple Negative Breast Cancer

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Saturday, April 27, 2013

Bio-Path's Plan to Develop Liposomal Grb-2 as a Targeted Therapy Against Inflammatory Breast Cancer and Triple Negative Breast Cancer

"...Focusing on its longer-term pipeline, the Company announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. Bio-Path’s plan is to develop Liposomal Grb-2 as a targeted therapy against TNBC and IBC. Treatment goals are two-pronged: the first being to develop Liposomal Grb-2 as a tumor reduction agent in combination with other approved drugs in pre-operative settings, and the second is to develop Liposomal Grb-2 as a drug to treat and control or eliminate cancer metastasis in TNBC and IBC patients. Both of these treatment goals address high need situations for patients..."

UPDATE July 22, 2013- "It is expected that after the completion of pre-clinical studies, a Phase I clinical trial in TNBC and IBC will be initiated by Bio- Path Holdings Inc. in 2014."
http://bionews-tx.com/news/2013/07/22/bio-path-holdings-initiates-development-of-liposomal-grb-2-for-triple-negative-and-inflammatory-breast-cancers/ (Click link to story)

http://www.rxir.com/SSI/ClientPR/201324102455.shtml (Link to story)

http://bionews-tx.com/news/2013/04/04/bio-path-holdings-expands-reach-of-non-toxic-md-anderson-tested-cancer-treatment/ (Link to story)

http://finance.yahoo.com/news/bio-path-shares-attractive-now-153340813.html (Link to story)

http://seekingalpha.com/instablog/685353-grant-zeng/1572271-bio-path-shares-are-attractive-now (Link to story)